Clinical Summary:

• Design/Population: In the phase 3 CHIPRO trial, patients with platinum-resistant or refractory ovarian cancer were randomly assigned to receive weekly paclitaxel plus chiauranib or weekly paclitaxel plus placebo.
• Key Outcomes: Chiauranib plus weekly paclitaxel significantly improved progression-free survival compared with weekly paclitaxel alone, with benefit observed regardless of prior antiangiogenic therapy exposure. Overall survival was similar between treatment groups at the time of analysis.
• Clinical Relevance: These findings support chiauranib plus weekly paclitaxel as a potential new treatment option for patients with platinum-resistant or refractory disease, including those previously exposed to antiangiogenic therapy. 

Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival (PFS) compared with weekly paclitaxel alone among patients with platinum-resistant or refractory ovarian cancer.

These results were presented by Xiaohua Wu, MD, Fudan University Shanghai Cancer Center, Shanghai, China, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

In this double-blind, placebo-controlled trial, 459 patients were randomized 1:1 to receive weekly paclitaxel with either chiauranib or placebo for up to 6 cycles followed by maintenance chiauranib or placebo in patients without progression. Stratification was based on prior lines of chemotherapy and platinum-free interval. Primary end points included PFS and overall survival (OS). A key secondary end point was safety. 

At a median follow-up of 16 months, median PFS was 4.57 months in the chiauranib arm and 2.69 months in the placebo arm (hazard ratio [HR], 0.427; 95% CI, 0.34 to 0.54; P < .001), representing a 57% reduction in the risk of progression. The PFS benefit was observed regardless of prior anti-angiogenic therapy exposure.

Median OS was 12.09 months and 12.12 months, respectively (HR, 0.932; 95% CI, 0.73 to 1.20; P = .583). A statistically significant OS benefit was observed in patients who did not receive subsequent anticancer therapy (HR, 0.599; 95% CI, 0.39 to 0.91; P = .016). Favorable OS trends were reported in patients who previously received PARP inhibitors and in those who subsequently received platinum-based chemotherapy.

The most common grade ≥3 treatment-emergent adverse events included leukopenia, neutropenia, and anemia. The safety profile was consistent with prior studies, and no new safety signals were identified.

“Chiauranib plus weekly paclitaxel significantly prolonged PFS in patients with platinum-resistant or refractory ovarian cancer, with a manageable and predictable safety profile,” concluded Dr Wu. “Significant benefit was also observed in the subgroup previously treated with antiangiogenic agents, supporting this regimen as a promising new treatment option.”

Source:

Wu X, Li J, Wang D, et al. A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer. Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. LBA5504.